News

Based on findings from the phase III BFORE trial, the FDA has approved Bosutinib as a first-line treatment for a chronic myeloid leukemia subtype.

The FDA approved abozantinib (Cabometyx) for use in previously untreated patients who have advanced renal cell carcinoma (RCC).

Using oral rivaroxaban (Xarelto) to treat patients with cancer reduced venous thromboembolism (VTE) recurrence in a select-d trial.

The FDA has granted a priority review to a supplemental new drug application (sNDA) for the use of osimertinib as a first-line treatment for patients with non-small cell lung cancer (NSCLC) whose tumors harbor EGFR mutations.

Patients with cancer who suffer severe distress are more likely to miss appointments during the course of their radiation therapy and be admitted to the hospital.

New trial results represent the first successful effort in more than 30 years to imrove outcomes of first-line treatment in patients with advanced Hodgkin lymphoma (HL).

The FDA has granted a priority review to a supplemental biologics license application (sBLA) for use of this combination as a frontline treatment for intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC).

A novel approach to the treatment of patients with smoldering multiple myeloma (SMM) produced durable results in a phase II trial.

Results of a phase I trial presented showed that the agent BLU-285 (Avapritinib) agent was well tolerated among patients with an advanced or aggressive form of systemic mastocytosis (ASM), a rare blood disorder that originates in mast cells.

Results of a new study show that adding ribociclib (Kisqali) to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival (PFS) when used as a first-line treatment for

A supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) has been granted FDA priority review status for the treatment of adults and children with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL).

The American Society of Clinical Oncology (ASCO) recently published a special article in the Journal of Clinical Oncology that idicated that even one alcoholic drink per day can increase cancer risk.

This PARP inhibitor therapy is more effective than chemotherapy in extending progression-free survival and reducing risk of death from BRCA-positive breast cancer.

Shortening the intervals between chemotherapy cycles or administering the drugs sequentially compared to current techniques reduces early-stage breast cancer recurrence and mortality, study shows.

PARP inhibitor Rucaparib may soon be available to a wider group of patients with ovarian cancer.

Bevacizumab (Avastin), a VEGF inhibitor, has been granted a full approval by the FDA for the treatment of adult patients with glioblastoma that progressed following prior therapy, according to its manufacturer, Genentech.

The researchers found that job lock was more common among survivors reporting previous health insurance denial and difficulties paying medical bills. Job lock was also more frequent among women and in survivors who had a severe, disabling, or life-threatening health condition.

Trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst), which is co-developed by Mylan and Biocon, has just been approved by the FDA for HER2-positive patients with breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma, the same indications as trastuzumab.

Most people surveyed think that the cost of cancer care is too high, and some even reported taking action that could jeopardize the outcomes of their treatments to bring the cost down.

The FDA has granted a priority review to a biologics license application (BLA) for mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least 1 prior systemic therapy, according to Kyowa Hakko Kirin, the manufacturer of the anti-CCR4 monoclonal antibody.

Although much success has been seen, 15% of patients with HER2-positive breast cancer will recur. Outcomes for those patients need to be improved, said Sara M. Tolaney, MD.

“Immunotherapy is a new option for patients and is well established,” said George R. Blumenschein, MD. “We are refining how we use it. There will be a number of additional refinements as we have the new data that will be coming forward in the next few months.”

Three CDK 4/6 inhibitors—palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio)— are game-changers in the field of breast cancer, explained Richard S. Finn, MD.

The American Society of Clinical Oncology, Friends of Cancer Research, and the Food and Drug Administration published clinical trial eligibility recommendations in a special issue of the Journal of Clinical Oncology that aim to broaden who can be accepted into clinical trials.

Adjuvant therapy is associated with high toxicity and most patients will derive no benefit, Umberto Capitanio, MD, San Raffaele Scientific Institute, Milan, Italy, said in a presentation during the 2017 EMUC Congress. However, adjuvant therapy “might show the highest ratio between clinical benefit and toxicity” in this specific subset of high-risk patients.

In an interview with Oncology Nursing News, the assistant professor at the Yale School of Nursing discussed a new standard of care with immunotherapy, common side effects, and why patients sometimes withhold information from their healthcare team.

“Are there ways that we can optimize the cure rates with HIFU? When are people recurring? What are we missing when they recur? What are the true rates of complications? We do not know the answer to most of these questions,” says Jonathan Warner, MD.

Palliative care can help alleviate physical symptoms or side effects, ease difficult emotions and anxiety, resolve worrisome questions and even prolong life.

Maria De Santis, MD, associate clinical professor at the University of Warwick, discussed the findings of KEYNOTE-045 and the future of immunotherapy in the treatment landscape of bladder cancer.

Advanced practice nurses, such as nurse practitioners (NPs), are increasingly specializing in their areas of practice. In response, specialty nursing organizations have delineated the scope and standards of advanced practice in these specialty areas.